Introduction:Basic information about LITHIUM CITRATE TETRAHYDRATE CAS 6080-58-6, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
LITHIUM CITRATE TETRAHYDRATE Basic information
| Product Name: | LITHIUM CITRATE TETRAHYDRATE |
| Synonyms: | TRI-LITHIUM CITRATE TETRAHYDRATE;LITHIUM CITRATE;LITHIUM CITRATE TETRAHYDRATE;CITRIC ACID TRILITHIUM SALT;CITRIC ACID, TRILITHIUM SALT TETRAHYDRATE;CITRIC ACID, 3LI, TETRAHYDRATE;Lithium citrate tribasic tetrahydrate;Tri-LithiumCitrateGr(Tetrahydrate) |
| CAS: | 6080-58-6 |
| MF: | C6H13Li3O11 |
| MW: | 281.98 |
| EINECS: | 612-032-8 |
| Product Categories: | GLYSET |
| Mol File: | 6080-58-6.mol |
|
LITHIUM CITRATE TETRAHYDRATE Chemical Properties
| Melting point | 112 °C |
| bulk density | 420kg/m3 |
| density | 1.64 at 20℃ |
| storage temp. | 2-8°C |
| solubility | H2O: 1 M at 20 °C, clear, colorless |
| form | Fine Crystalline Powder |
| color | White |
| Odor | Odorless |
| PH | 8.0-9.5 (25℃, 1M in H2O) |
| PH Range | 8.0 - 9.5 at 209.8 g/l at 25 °C |
| Water Solubility | 209.8 g/l at 20 °C |
| λmax | λ: 260 nm Amax: 0.040 λ: 280 nm Amax: 0.016 |
| Merck | 13,5552 |
| Stability: | Stable. Incompatible with strong oxidizing agents, reducing agents, bases. |
| InChI | 1S/C6H8O7.3Li.4H2O/c7-3(8)1-6(13,5(11)12)2-4(9)10;;;;;;;/h13H,1-2H2,(H,7,8)(H,9,10)(H,11,12);;;;4*1H2/q;3*+1;;;;/p-3 |
| InChIKey | HXGWMCJZLNWEBC-UHFFFAOYSA-K |
| SMILES | [Li+].[Li+].[Li+].O.O.O.O.OC(CC([O-])=O)(CC([O-])=O)C([O-])=O |
| LogP | -1.72--1.67 at 20-25℃ |
| CAS DataBase Reference | 6080-58-6(CAS DataBase Reference) |
Safety Information
| Hazard Codes | Xi |
| Risk Statements | 36/37/38 |
| Safety Statements | 26-36 |
| WGK Germany | 1 |
| F | 3 |
| HS Code | 29181500 |
| Storage Class | 11 - Combustible Solids |
| Hazard Classifications | Acute Tox. 4 Oral |
LITHIUM CITRATE TETRAHYDRATE Usage And Synthesis
| Chemical Properties | White crystalline powder |
| Uses | alpha-glucosidase inhibitor, antidiabetic |
| Uses | Lithium citrate is useful as a potential therapeutic for Canavan disease due to aspartoacylase deficiency or aminoacylase 2 deficiency. |
| Application | Citric acid trilithium salt tetrahydrate is a pharmaceutical structural material commonly used in the determination of amino acids by high-performance liquid chromatography gradient elution. |
| Definition | ChEBI: A hydrate that is the tetrahydrate form of lithium citrate. It is used as a source of lithium for the treatment of anxiety disorders, bipolar disorder, and depression. |
| Brand name | Lithonate (Solvay Pharmaceuticals). |
LITHIUM CITRATE TETRAHYDRATE Preparation Products And Raw materials